Moreover, in a phase II trial in ovarian cancer patients carrying germ-line mutations of BRCA1 or BRCA2 genes, a synergistic effect of olaparib (PARPis), when combined with durvalumab (ICB), was demonstrated. Here, BRCA1 is linked to ovarian carcinoma.